Literature DB >> 18406454

Drugs that interact with cardiac electro-mechanics: old and new targets for treatment.

Paulus Kirchhof1, Lisa Fortmüller, Christoph Waldeyer, Günter Breithardt, Larissa Fabritz.   

Abstract

The concept of mechano-electrical feedback was derived from the observation that a short stretch applied to the beating heart can invoke an electrical response in the form of an afterdepolarization or a premature ventricular beat. More recent work has identified stretch-activated channels whose specific inhibition might help to treat atrial fibrillation in the near future. But the interaction between electrical and mechanical function of the heart is a continuum from short-term (within milliseconds) to long-term (within weeks or months) effects. The long-term effects of pressure overload have been well-described on the molecular and cellular level, and substances that interact with these processes are used in clinical routine in the care of patients with cardiac hypertrophy and heart failure. These treatments help to prevent lethal arrhythmias (sudden death) and potentially atrial fibrillation. The intermediate interaction between mechanical and electrical function of the heart is less well-understood. Several recently identified regulatory mechanisms may provide novel antiarrhythmic targets associated with the "intermediate" response of the myocardium to stretch.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406454     DOI: 10.1016/j.pbiomolbio.2008.02.003

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  2 in total

Review 1.  Mechanotransduction in cardiac hypertrophy and failure.

Authors:  Robert C Lyon; Fabian Zanella; Jeffrey H Omens; Farah Sheikh
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

2.  A new preclinical biomarker for risk of Torsades de Pointes: drug-induced reduction of the cardiac electromechanical window.

Authors:  Hugo M Vargas
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.